ArticleClinical pharmacology and therapeutics2026
Population Pharmacokinetics and Exposure-Response Analyses of Momelotinib, Its Active Metabolite (M21), and Total Active Moiety in Myelofibrosis.
Article in Clinical pharmacology and therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Inflammatory and Immune Microenvironment in Myeloproliferative Neoplasms: Pathogenic Mechanisms and Therapeutic Opportunities.Cancers · 2026Review
- Rechallenge of ruxolitinib after momelotinib-related toxicity in a 74-yo woman with secondary myelofibrosis: a case report.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Momelotinib, a Janus kinase (JAK) 1/JAK2/activin A receptor type 1 inhibitor, is approved for the treatment of myelofibrosis with anemia. These analyses characterized the population pharmacokinetics of momelotinib and its active metabolite M21 following administration of the commercial tablet formulation in patients with myelofibrosis from phase II/III trials and other participants from phase I trials (N = 661). Predicted covariate effects on momelotinib, M21, and total active moiety (TAM)-representing the combined potency-weighted exposures of momelotinib and M21-exposures following 200-mg once-daily dosing were evaluated using a simulation-based approach. Using sequential modeling, momelotinib was described by a two-compartment model with six transit absorption compartments and first-order elimination, and M21 by a two-compartment model with first-order elimination. Hepatic function, concomitant CYP3A4 inducers, and concomitant OATP1B1/1B3 inhibitors were significant momelotinib covariates, while baseline creatinine clearance and hepatic function were significant M21 covariates, with cumulative effects on TAM. Exposure-response relationships between the average TAM concentration under actual dosing and key efficacy and safety end points were assessed using data from the 24-week randomized period of three phase III trials in patients with myelofibrosis (N = 417). After relevant covariate adjustment, significant positive relationships were identified with spleen volume reduction and transfusion independence (the latter specifically in JAK inhibitor-experienced patients), but not symptom improvement. Greater TAM exposure was significantly associated with lower odds of grade 3/4 anemia and higher odds of any-grade peripheral neuropathy, although the latter was infrequently observed in phase III trials. There was no significant relationship with grade ≥ 3 thrombocytopenia or any-grade diarrhea.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.